China Bans Indian-Made Drugs: Sun Pharma and Supriya Lifescience Face Suspension Over Safety Lapses

In a major blow to India’s pharmaceutical export reputation, China’s National Medical Products Administration (NMPA) has indefinitely suspended the import, sale, and use of two major products from top Indian manufacturers. The decision, announced on January 26, 2026, follows a series of rigorous inspections that uncovered systemic quality failures and alarming hygiene lapses at production sites in India.

The Affected Products & Manufacturers

The ban impacts a critical dementia medication and a high-volume raw material (API) used in common cold and allergy medicines.

Manufacturer	Product	Category	Primary Findings
Sun Pharma	Rivastigmine Hydrogen Tartrate Capsules	Dementia/Alzheimer’s	Contamination risks & poor risk management.
Supriya Lifescience	Chlorpheniramine Maleate (API)	Antihistamine	Pest control failure (insects/animals) & batch non-compliance.

1. Sun Pharma: systemic Quality “Incapacity”

A remote inspection of Sun Pharma’s oral capsule facility (located in the Dadra union territory) revealed that the company’s quality management team lacked the capability to identify and control risks for batches already sold in the Chinese market.

The Contamination Factor: Inspectors flagged “subpar prevention of contamination” and a failure to meet the standards set by the Pharmacopoeia of the People’s Republic of China.
US FDA Echoes: Notably, this same facility received a U.S. FDA warning letter in 2024 for “significant violations,” including stagnant liquid found in manufacturing equipment and inadequate cleaning protocols.

2. Supriya Lifescience: A “Lax” Environment

Supriya Lifescience, one of the world’s largest producers of Chlorpheniramine Maleate, faced an even more visceral critique after an on-site inspection.

Sanitation Failure: Regulators described facility management as “lax,” noting a failure to prevent insects and animals from entering production areas.
Downgraded Status: The API’s registration has been changed to a category that prevents it from being used in any finished drug formulations within China. This marks the second time Supriya has been banned in China (the first being in 2020).

Mandatory Actions & Regulatory Impact

The NMPA has issued a nationwide directive with immediate effect:

Customs Freeze: Customs authorities have been instructed to stop issuing import permits and freeze all incoming shipments for both products.
Usage Halt: Hospitals, clinics, and pharmacies across China must immediately stop using and selling the affected capsules and API.
Industry Investigation: Chinese pharmaceutical companies that use Supriya’s API in their own products must conduct urgent risk assessments and implement control measures to protect consumers.

Strategic Context

The ban comes at a sensitive time for Indian pharma in China. While Indian generic manufacturers have recently won several rounds of China’s Centralized Procurement (VBP), these quality failures provide ammunition for critics of cross-border sourcing. For Sun Pharma, the loss of the Alzheimer’s segment in China—a market seeing explosive demand due to an aging population—is a significant financial setback.